Any current/future new fundraising through debt or equity?

The company plans to fund its upcoming CAPEX of around Rs. 100 crores over the next 2 years through a mix of internal accruals and borrowings. Debt-equity ratio target is maintained between 0.3 and 0.35, indicating careful monitoring of leverage. No explicit mention of equity fundraising in the current or near future. The planned CAPEX totaling Rs. 400 to Rs. 500 crores over the next 12 to 18 months (including Atali expansion, solar projects, and Xanthine capacity) will also be funded via internal accruals and some borrowings. The company is well-positioned in terms of debt-equities and busine

Any current/future capex/capital investment/strategic investment?

Greenfield expansion project at Atali site: Rs. 375 crore CAPEX, targeted for completion in H2 FY25. This large manufacturing site will be developed in phases with multiple blocks, expanding capabilities including peptides and flow chemistry. Xanthine primary raw material manufacturing project: Expected to start in Q4 FY24, reducing import dependency. Semi-commercial production block at US FDA intermediate manufacturing site in Vapi: Aiming for completion in Q2 FY25. Additional generic capacity expansion planned over next 15-18 months, with total CAPEX for 2024-25 estimated between Rs. 400

Future growth expectations in sales/revenue/volumes?

Xanthine segment shows volume growth of around 3.5% YTD compared to last year, with expectations of 7-8% increase next fiscal due to debottlenecking initiatives. CDMO & CMO segment anticipated to grow rapidly, with 40-50% growth expected next year and potential to make up 20-25% of total revenue in 2-3 years. API and Intermediate segment expected to grow steadily, with a target of 15-20% revenue growth over next 2 years, despite pricing pressures. Overall company EBITDA expected to grow 8-10% in FY24 and 12-17% annually over the next 2-3 years. New product launches and increased customer base

Future growth expectations in earnings/operating earnings/profits/EPS?

FY24 EBITDA growth expected around 8-10% (Rashesh Gogri, page 14). Long-term EBITDA growth guidance is 12-17% annually over the next 2-3 years (page 14). PAT for Q3 FY24 was Rs. 53 crores, EPS at Rs. 5.82 per share; an interim dividend of Rs. 2 per share was declared (page 3). The company aims for sustained growth driven by capacity expansions, new product launches, and increasing share of CDMO/CMO business (pages 3, 10). CDMO/CMO segment targeted to grow at 40-50% annually; expected to contribute 20-25% or more of total revenue in next 2-3 years (pages 10, 6). Absolute EBITDA increases prefer

IN US

Sale is live|00:00:00left today

Aarti Pharmalabs LtdQ4 FY25Pharmaceuticals & Biotechnology

Aarti Pharmalabs Ltd Q4 FY25 Earnings Call Analysis

Revenue, margin, capex, fundraise and order book outlook from management commentary.

Price: ₹691P/E: 29.9Market Cap: ₹6.5K CrSector: Pharmaceuticals & Biotechnology

Management growth scorecard

Revenue

Category 3

Margin

Category 3

Fundraise

Yes

Order

N/A

Capex

Yes

2 of 4 growth signals are positive.

Full analysis

Revenue guidance

Category 3

→Xanthine segment shows volume growth of around 3.5% YTD compared to last year, with expectations of 7-8% increase next fiscal due to debottlenecking initiatives.
→CDMO & CMO segment anticipated to grow rapidly, with 40-50% growth expected next year and potential to make up 20-25% of total revenue in 2-3 years.
→API and Intermediate segment expected to grow steadily, with a target of 15-20% revenue growth over next 2 years, despite pricing pressures.
→Overall company EBITDA expected to grow 8-10% in FY24 and 12-17% annually over the next 2-3 years.
→New product launches and increased customer base in CDMO and API segments to drive growth.
→Greenfield expansion projects and capacity increases at Atali and Xanthine sites aimed at supporting long-term growth and enhanced volumes.

Margin guidance

Category 3

→FY24 EBITDA growth expected around 8-10% (Rashesh Gogri, page 14).
→Long-term EBITDA growth guidance is 12-17% annually over the next 2-3 years (page 14).
→PAT for Q3 FY24 was Rs. 53 crores, EPS at Rs. 5.82 per share; an interim dividend of Rs. 2 per share was declared (page 3).
→The company aims for sustained growth driven by capacity expansions, new product launches, and increasing share of CDMO/CMO business (pages 3, 10).
→CDMO/CMO segment targeted to grow at 40-50% annually; expected to contribute 20-25% or more of total revenue in next 2-3 years (pages 10, 6).
→Absolute EBITDA increases preferred over percentage margin growth due to pricing pressures in segments like Xanthine (pages 8, 7).
→Overall, the company is well-positioned for earnings growth backed by expansions and new capabilities (pages 3, 14).

3 more insights locked — sign up free to unlock

Fundraise plans

Yes

→The company plans to fund its upcoming CAPEX of around Rs. 100 crores over the next 2 years through a mix of internal accruals and borrowings.
→Debt-equity ratio target is maintained between 0.3 and 0.35, indicating careful monitoring of leverage.
→No explicit mention of equity fundraising in the current or near future.
→The planned CAPEX totaling Rs. 400 to Rs. 500 crores over the next 12 to 18 months (including Atali expansion, solar projects, and Xanthine capacity) will also be funded via internal accruals and some borrowings.
→The company is well-positioned in terms of debt-equities and business opportunities to support expansion without aggressive new fundraising.

Order book

The transcript does not provide explicit details on the current or expected order book or pending orders in quantified terms. However, relevant insights can be summarized as: - The company has a diverse product basket with 39 products in CDMO across 16 customers in various development and commercial stages. - Ramp-up in CDMO projects is expected to continue, indicating a growing/potential order book. - Some postponement of orders has led to shifting sales to the next financial year. - The ramp-up of new products in CDMO and new customer additions indicate positive order pipeline visibility. - The large Greenfield Atali project and expansion efforts reflect confidence in future demand. - Xanthine pricing pressure is expected to last till mid-next year, but volumes have grown about 3.5% year-to-date. - The company expects EBITDA growth of 8-10% for FY24 and 12-17% over the next 2-3 years supported by order ramps. No direct figures on pending or confirmed orders were disclosed.

Capex plans

Yes

→Greenfield expansion project at Atali site: Rs. 375 crore CAPEX, targeted for completion in H2 FY25. This large manufacturing site will be developed in phases with multiple blocks, expanding capabilities including peptides and flow chemistry.
→Xanthine primary raw material manufacturing project: Expected to start in Q4 FY24, reducing import dependency.
→Semi-commercial production block at US FDA intermediate manufacturing site in Vapi: Aiming for completion in Q2 FY25.
→Additional generic capacity expansion planned over next 15-18 months, with total CAPEX for 2024-25 estimated between Rs. 400 to Rs. 500 crore, including Rs. 90 crore for solar energy projects.
→CAPEX funding mix: Internal accruals and borrowings while maintaining a target debt-equity ratio between 0.3 and 0.35.
→Solar CAPEX (~Rs. 90 crore) will begin operating by H2 FY25, expected to reduce energy costs.

How does Aarti Pharmalabs Ltd rank vs peers in Pharmaceuticals & Biotechnology?

Pro feature

1Aarti Pharmalabs Ltd

Rev 3Mar 3

See full Pharmaceuticals & Biotechnology sector rankings

Want more stocks like Aarti Pharmalabs Ltd?

Build an AI portfolio filtered by sector, market cap, and growth rank. Takes 2 minutes.

Build my portfolio